At HC21, we partner with world-leading manufacturers to bring the most innovative solutions to the market, with the aim of improving clinical outcomes. Clinical research is fundamental to ensure that the latest innovative treatments are safe and fit for purpose.
Our Aquilant team is delighted to see the positive results of the PRESERVE study, confirming the important role that NanoKnife plays in the treatment of intermediate-risk prostate cancer, whilst preserving quality of life.
The PRESERVE study assessed the use of the Nanoknife in the treatment of over 120 patients across 17 centres in the United States. All institutions and surgeons involved in the study were highly experienced providers of focal therapy, with each surgeon having completed a standardised training programme covering the fundamentals of IRE, including safe and effective surgical techniques.
Read the study here: https://www.sciencedirect.com/science/article/abs/pii/S030228382500346X
United Kingdom
Ireland